Cholelithiasis Gallstones Gallbladder Disease

Introduction
Gallbladder disease, especially cholelithiasis (gallstones) affects over 20 million Americans every year. The condition often goes undiagnosed because cholelithiasis rarely presents symptoms. Abdominal discomfort, nausea, jaundice and biliary colic are some symptoms of the condition. Imaging techniques are the most accurate diagnosis tools for gallbladder diseases. However, laboratory values such as CBC, serum amylase, liver-function testing and lipase can help differentiate the type of gallbladder disease/or identify related issues. Surgery is the most effective treatment for gallbladder disease patients. Exercise, diet, and nutrition affect gallbladder disease. It is important for patients to integrate the healthy habits into their lifestyle to lower the risk of developing gallbladder disorders (Jugenheimer, et al., 2008).
Cholelithiasis (gallstones) is the most common type of gallbladder disease. It affects over 20 million Americans every year, translating to over $6.3 billion in direct costs. Generally, gallstones are asymptomatic. The stones are usually identified during autopsy or a surgical procedure of an unrelated condition. The condition is the most common inpatient diagnosis among liver and gastrointestinal diseases in the United States. Although the disease is asymptomatic, patients can progress into symptomatic condition of the disease. Cholecystitis (gallbladder inflammation) is the main clinical manifestation and effect of cholelithiasis. Severe cases of the disease may develop gallbladder perforation, gallstone pancreatitis or any other gallbladder disease (In Cox et al., 2018).
Cholecystectomy is a surgical procedure aimed at gallbladder removal. The organ lies below the liver on the top right side of the abdomen. It is responsible for bile collection and storage. Bile is a digestive fluid secreted in the liver. The surgery has a small risk of complications, with the possibility of same-day discharge after the surgery. A tiny video camera and other special surgical tools are inserted into the abdomen via four small incisions for gallbladder observation and removal. The process is known as laparoscopic cholecystectomy. On the other hand, open cholecystectomy involves the use of one large incision during surgery. The surgery minimizes trauma that may be experienced during the interventional process while facilitating satisfactory therapeutic outcomes (Jugenheimer, et al., 2008).
The surgery promotes faster recovery and hastens return to normal life, shortens hospital stay, and reduces postoperative pain and pulmonary complications, explaining its preference as the mode of treatment for cholecystitis. It also reduced stress response, postoperative wound infection rate, respiratory function impairment, intraoperative bleeding and cosmetic appearance. Although it shortens hospital stay, it has no general effect on postoperative mortality. Clinical findings, patient characteristics, and the experience of a surgeon determine the patient’s risk factors for perioperative complications. The benefits of the procedure must outweigh the effects of carbon dioxide used during surgery (In Cox et al., 2018).
The patient’s name is Marie Peter, born on 19/09/38. The female patient’s URL is 012345. She was rushed to St. Thomas hospital emergency department at 1730. The patient was admitted after being diagnosed with post-cholecystectomy- TF ongoing abdominal pain. She was accompanied to the hospital by her husband and daughter. She requires ongoing care forward: D/C still drain Insitu. The paper looks into her case from the pathophysiology of cholecystectomy and pharmacokinetics of her medication, including GORD and T2DM (Jugenheimer, et al., 2008).
Pathophysiology of Cholecystectomy
Cholecystectomy has respiratory and cardiovascular effects, including other body systems. Gallstones are hard, stone-like masses that block the cystic duct. The presence of biliary sludge, calcium deposits, a viscous mixture of glycoproteins, and cholesterol crystals in biliary ducts or the gallbladder lead to the development of gallstones (Borzellino & Cordiano, 2008). Gallstones among patients in the U.S mainly comprise of bile with high saturation of cholesterol. The super saturation (cholesterol is higher in concentration than its solubility percentage) results due to hyper secretion of cholesterol resulting from hepatic cholesterol metabolism alteration. A change in balance between antinucleating (crystallization-inhibiting) and pronucleating (crystallization-promoting) proteins in the bile can speed up cholesterol crystallization in the bile. Biliary epithelial cells secrete mucin, a glycoprotein mixture and a pronucleating protein. Decreased mucin degradation by lysosomal enzymes facilitates the development of cholesterol crystals (Borzellino & Cordiano, 2008).
Gallstone development also results from excessive sphincteric contraction and gallbladder muscular-wall motility loss. The hypomotility results in prolonged bile stasis (delayed emptying on the gallbladder), and reduction function of the reservoir (Jugenheimer, et al., 2008). Increased predisposition for stone development and bile accumulation results from failure of bile to flow. Increased hepatic bile proportion being diverted to the small bile duct from the gallbladder and ineffective filling can result due to hypomotility. Sometimes, gallstones comprise of a chemical produced from RBCs standard breakdown known as bilirubin. Bilirubin stone development results from increased enterohepatic bilirubin cycling and biliary tract infection. Bilirubin stones, also known as pigment stones, manifest in patients with biliary tract infections or chronic hemolytic diseases (or damaged RBCs). Pigment stones are more prevalent in Africa and Asia (Jugenheimer, et al., 2008).
Cholecystitis pathogenesis includes Hartmann’s pouch, effect of gallstones in the neck of the bladder, or the cystic duct; however, cholecystitis does not always present gallstones. Enlargement of the organ, increase in gallbladder pressure, decrease in blood supply, thickening walls, and formation of an exudate can also occur. Cholecystitis is either chronic or acute, with a cycle of acute inflammation. The inflammation may lead to the condition becoming chronic. Various microorganism such as the gas-forming types can infect the gallbladder. Gangrene and necrosis can occur in an inflamed gallbladder, progressing into symptomatic sepsis if not treated. Lack of proper cholecystitis treatment may lead to gallbladder perforation, a phenomenon that is rare, but life-threatening. If stones dislodge in the gallbladder down to the Oddi Sphincter, gallstone pancreatitis develops if clearance of the stone traces does not take place. The result is the pancreatic duct getting blocked (Borzellino & Cordiano, 2008).
Pharmacokinetics Related to Her Medication
Variations in patient positioning and intra-abdominal CO2 insufflation’s physiological effects can heavily impact the cardiorespiratory function. Moreover, anesthesia’s resulting effects produce a distinct hemodynamic response. Proper understanding of the physiological changes is key to maximum anesthetic care. Inhalation agents, intravenous drugs and muscle relaxants are used for anesthetic care. Drugs with short actions such as atracurirm, propofol, sevoflurane, vecuronium or desflurane are used as maintenance drugs. Assessments and procedures before the surgery, proper monitoring and a high suspicion index can help with diagnosis and treatment of complications in their early stages (Vizi et al., 2014).
The patient was given a prescription of Paracetamol and Panadol, among other pain management medications. She was also given antibiotics and other medications for pain management. The drugs are readily absorbed from the gastrointestinal (GI) tract. After 30 minutes to an hour of taking an oral dose, plasma concentrations hit peak levels. Ranging from 70-90%, the drugs’ systemic bioavailability is dependent on the dosage given. The drugs are distributed across various body tissues and the liver is responsible for metabolizing them. With half-life varying from 1 to 6 hours, the metabolites of the drugs are excreted in urine. However, they are inactivated if therapeutic doses are administered. Therefore, the medications are not just effective, but also safe (Vizi et al., 2014).
Pathophysiology of GORD
After eating, many people experience reflux of the food in the stomach into the oesophagus, making it a normal physiological occurrence. Grastro-oesophageal reflux disease (GORD) is when gastric reflux results in symptoms and/or complications. It is a range of disorders such as erosive oesophagitis, non-erosive reflux disease, oesophageal adenocarcinoma, and Barrett’s oesophagus. At least every couple of days in a week, about 15% to 20% of adults experience heartburn, a typical symptom of GORD. Proton pump inhibitors (PPIs) are used for short-term GORD diagnosis, and to support erosive lesions healing, including long-term control of symptoms on a daily basis or “as needed.” Further investigation is recommended for symptoms that do not respond to treatment or uncertain diagnosis of patients (Bullock et al., 2012).
Gastric reflux results from periodic lower oesophageal sphincter relaxation. It exposes the oesophagus’ squamous mucosa, prone to damage, to bile salts, proteolyticenzymes (such as trypsin and pepsin) and acid. Consistent gastric reflux exposure can result in oesophagitis, visible on endoscopy in some patients. However, two-thirds of patients diagnosed with GORD do not present visible signs. GORD symptoms, for many patients, results from abnormal spaces being present in the mucosa epithelium. It causes excessive stimulation of peripheral sensitization and nerve endings. Heartburn also occurs in the form of gas reflux, without any gastric fluid reflux. GORD symptoms that do not respond to PPI treatment could point to gas reflux causing mechanoceptors distension in the oesophageal wall (Talley, 2011).
An empty stomach produces the highest amount of acid. However, patients experience GORD after taking a meal, when the production of the acid is lowest. After eating, the stomach’s proximal region forms an unbuffered acid volume known as the acid pocket. Hiatus hernia can worsen or cause GORD; the condition develops due to displacement of the oesophageal junction (Talley, 2011). Severe GORD is often related to hiatus hernia, a condition that endoscopy can easily diagnose. It is also related to impaired gastric clearance or oesophageal, reducing the speed at which food moves down the digestive tract. Central obesity, also associated with GORD, increases the pressure gradient between the thorax and the abdomen, hence increasing reflux episodes and the risk of hiatus hernia. About 60% of patients with GORD attribute their symptoms to stress. Lifestyle and diet such as spicy foods, high-fat foods, alcohol, caffeine and smoking can worsen GORD symptoms (Bullock et al., 2012).
Pharmacokinetics Related to the Medication She is taking
Esomeprazole tab (EC) or omeprazole 20mg daily is used to treat GORD and/or manage its symptoms. The absorption of the drug occurs in the small intestine within 3 to 6 hours. The systemic bioavailability of the drugs after being taken repeatedly is almost 60%. Its distribution volume is 0.4 L/kg. The drugs have a high plasma protein binding of 95%. PPIs such as omeprazole and esomeprazole, are effective on active K /H -ATPase pumps only. The presence of food stimulates the pumps to facilitate digestion. Therefore, the drug should be taken with a glass of water on an empty stomach (Anderson et al., 2010).
Moreover, patients should not eat for a minimum of half an hour after taking the drug. However, sodium bicarbonate drugs such as Zegerid and immediate-release omeprazole requires up to an hour before eating. The cytochrome P450 system totally metabolizes the drug, in the liver. Sulfide and sulfone metabolites, and hydroxyl-esomeprazole exert no major effect on secretion of acid in the stomach. Almost 77% of the oral drugs are excreted as metabolites in urine, and the remaining 23% in feces, mainly from bile secretion. The drug has a half-life of 0.5 to 1 hour. Esomeprazole’s pharmacological effects last longer because it is bonded to proton pump covalently on parietal cells to induce effects (Anderson et al., 2010).
Pathophysiology of T2DM
Type 2 diabetes mellitus is a heterogeneous disorder. Its prevalence varies among various ethnicities. Hispanic Americans, Native Americans mostly in the desert Southwest, and Asian-Americans are the populations in the U.S most vulnerable to T2DM. Peripheral insulin resistance, declining ?-cell function (may lead to ?-cell failure), and impaired hepatic glucose production regulation make up the pathophysiology of T2DM. In most patients, the primary pathophysiology event is an initial deficit in secretion of insulin. The deficit is relative to peripheral insulin resistance (Nahikian-Nelms & Sucher, 2015).
Pharmacokinetics Related to the Medication She is taking
Administration of insulin through SQ injection results in its direct absorption into the bloodstream. The lymphatic system plays a small role in the transportation of insulin. After SQ absorption, insulin absorption into the bloodstream is insulin activity’s limiting step. The variation coefficients of T50% (the time it takes for 50% of the insulin dose to be absorbed) varies, making absorption inconsistent. The rate is 25% in individual patients and 50% between different patients. The difference in blood flow at various injection sites (gluteus, deltoid, thigh and abdomen) is attributed to the variation in insulin absorption. Unlike other subcutaneous injection sites, the absorption of regular insulin from the abdomen in twice faster. Patients should avoid random use of different parts of the body for insulin injections (Krentz, 2012).
For instance, if the thigh is used for noontime injections, it should be maintained. However, the abdomen is less susceptible to factors impacting absorption of insulin, making it the preferred injection site. Insulin glulisine, aspart and lispro vary less in rates of absorption on a day-to-day basis, and based on different injection sites on the body. For insulin glargine, the pharmacokinetic profile after deltoid, abdominal or thigh SQ injections is similar. Similarly, insulin degludec’s effect on lowering glucose is consistent when injection is done on the upper arm, abdomen or thigh SQ sites (Krentz, 2012). Alteration of local blood flow in SQ sites is responsible for altering insulin absorption. Factors that increase blood flow at SQ sites raise the rate of absorption. Exercise of injected areas, temperature, local massage, lipohypertrophy, injection site, jet injectors, insulin dose, insulin mixtures and soluble vs. suspensions insulin (physical status) influence the absorption rate of insulin into the bloodstream.
Insulin degradation occurs in the liver and kidneys. Whereas the kidneys degrade 35% to 45% of insulin the pancreases releases into the portal vein, 50% to 60% is degraded in the liver. Exogenous insulin injection alters its degradation profile because it is not delivered directly into the vein. The liver degrades 30-40% of SQ insulin while the kidneys partake 60%, making it a major player in insulin degradation. Renal dysfunction reduces insulin clearance and prolongs its effect because kidneys degrade a large portion of insulin injected in the body. This is true for both exogenous insulin injections and endogenous insulin production (oral-agent stimulated or normal production). However, this happens only after kidney’s renal function is greatly diminished. With renal function deterioration, exogenous insulin requirements declines progressively, and the risk for hypoglycemia increases (Krentz, 2012).
Investigation
The patient has a background of PMHx: T2DM, GORD, osteoarthritis, HTN, Depression, Asthma, Cholecystitis, IVAD, Right total hip replacement, and NSTEMI. Gallbladder disease diagnosis is currently less invasive, enabling patients to recover faster than with traditional diagnostic procedures. Despite the high cholelithiasis prevalence in the United States, most patients do not present symptoms. This does not just complicate diagnosis, but prolongs it. Liver-function testing, CBC, serum amylase and lipase are laboratory tests included in the diagnosis process to screen for the various gallbladder disease types and/or identify related complications. Pancreatic gallstones (abnormal liver function test; high amylase and lipase), biliary colic (no major changes in lab data; acute pain with high liver enzymes and bilirubin may present), acute cholecystitis (mild increase in alkaline phosphate and/or bilirubin; leukocytosis), choledocholithiasis (high liver enzymes and bilirubin) and chronic cholecystitis (normal lab values) are some common gallbladder diseases (AL-alem et al., 2017).
Various imaging technologies can verify the various gallbladder diseases. Ultrasonography and cholescintigraphy are the most common imaging techniques for cholecystitis and cholelithiasis diagnosis. Positive findings from the ultrasonography imaging include gallbladder wall thickening, stones, Murphy’s sign (pain) upon contact with the probe in use, and pericholecystic fluid. When performed in the fasting state, correct diagnosis is done in over 90% of patient cases. However, 50% of patient cases miss bile-duct stones. Also known as hepatobiliary iminodiacetic acid (HIDA) scan, cholescintigraphy screens gallbladder function to diagnose cholecystitis. However, the scans are not effective for chronic cholecystitis or cholelithiasis diagnoses (In Wang & In Portincasa, 2017).
Cholescintigraphy offers accurate diagnosis in over 95% of ambulatory patients. However, it may produce incorrect findings in 30% - 40% of hospitalized patients, especially those under parenteral nutrition. Therefore, ultrasonography is the preferred diagnostic tool for such patients. If the dye or radioactive tracer does not visualize the gallbladder, cholescintigraphy results are categorized as abnormal. The same applies to cases where the gallbladder is detected outside the biliary system or the dye moves slowly across the bile ducts. Endoscopic retrograde cholangiopancreatography (ERCP) is handy if choledocholithiasis is a likely diagnosis. ERCP identifies common bile-duct stones for removal. ERCP is related to complications such as pancreatitis. Endoscopic ultrasonography and other noninvasive techniques detect cholelithiasis, but does not support stone removal (AL-alem et al., 2017).
Although CT can also be used for diagnosis, it is less accurate than other imaging techniques, and detects about 75% of gallstones, only. On the other hand, magnetic resonance, cholangiopancreatography (MRCP) detects biliary tract abnormalities such as choledocholithiasis. Its sensitivity is about 98%. Generally, lab Investigation include a general report XR Chest, blood test, CT drainage, DF drainage biliary tube check, Troponin T level, CT brain check, CT Abdo pelvis, PTH drain, and AN cholangiogram. On the other hand, clinical assessment include MRSA screen. Action after surgical review includes IVAB’s, MSSU, ACAT for respite TCP, Observation 4/24, Drain Insitu, PT/OT, BGL-QID, Oral analgesia, multiple allergies, Triflow (In Wang & In Portincasa, 2017).
Assessment
Cholecystectomy puts the patient at risk of various complications. They include bleeding, bile leak, infection, injury to nearby organs such as liver, bile duct and small intestine, pneumonia and blood clots from anesthesia use, tear of abdominal wall, pneumothorax, pneumopericardium, urinary tract injuries, gastrointestinal tract injuries, etc. Postcholecystectomy syndrome (PCS) is a temporary diagnosis (Lemone, 2013). A functional or organic diagnosis is carried out. Post-anesthesia care is provided to foster return to normal life and activities. Proper ventilation is provided if the patient has respiratory issues. Postoperative pain is the most imminent. Opioids, local anesthesia, multimodal analgesia, nonsteroidal anti-inflammatory drugs and preprocedure parecoxib administration are effective for clinical care and pain management. Low opioid doses and use of multimodal analgesia drugs reduces cases of postoperative nausea and vomiting. The patient was mainly given pain killers and antibiotics to manage pain and prevent or stop infections on the wounds to promote faster postoperative recovery (Lemone, 2013).
Recommendation
Patients diagnosed with asymptomatic cholelithiasis do not need treatment. However, laparoscopic cholecystectomy is recommended for symptomatic cholelithiasis treatment. The traditional form of treatment was open cholecystectomy. Percutaneous cholecystectomy is another surgical procedure for the disease. Unlike the traditional surgical procedure, laparoscopic cholecystectomy promotes faster recovery and shorter hospital stay. Contraindications include an intractable bleeding disorder, inability to withstand anesthesia generally, and end-stage liver disease. Internal gallbladder stent endoscopic decompression prevents the development of complications and supports long-term palliative treatment in patients who are either unwilling or unable to undergo a surgical procedure. Another option for such patients include non-operative therapy such as gallstones dissolution using shock wave lithotripsy and oral bile acids (Jugenheimer, et al., 2008).
However, it is time-consuming, less effective, expensive, and has a high rate of recurrence. Ursodeoxycholic acid (ursodiol) and chenodeoxycholic acid (chenodiol) are some oral bile acids often used to dissolve gallstones. They are effective for small stones measuring 0.5 to 1 cm, and make work over two years to clear the stones. Ursodiol is the most popular oral bile acid due to its safe side effects in comparison to chenodiol. The latter is associated with diarrhea dependent on the dose. Other effects include hepatotoxicity, leukopenia, and hypercholesterolemia, limiting its application (In Agresta et al., 2014).
Changes in lifestyle and nutrition can prevent and treat cholelithiasis. Increased risk of the gallbladder disease is associated with obesity, making weight loss essential to prevention of gallstone development. However, rapid weight loss may facilitate the development of gallstones. Monounsaturated fats, polyunsaturated fats, caffeine and fiber can help prevent the formation of gallstones. Moderate alcohol and fish oil consumption has been proven to reduce triglycerides, increase HDL, and reduce saturation of bile cholesterol, making them good additions to patient diets. Hospitalization is necessary for patients diagnosed with acute cholecystitis for parenteral fluids and nutrition, total bed rest, and IV antibiotics to be provided (In Agresta et al., 2014).
The recommendations for physiotherapy include wearing incontinent pad, X1 mobility to walk to toilet with 4 wheel walker, assessment for fall risk, behavior/cognition, skin integrity, monitoring of surgical drainage site and ongoing management care, hygiene and X1 assist. The dietitian’s reason for referral is poor diet intake. Ward diet intake is recommended. Estimated nutrition intake intervention include energy (EER): 8500-10625KJ, protein (EPR): 68-85g, fluid (EFR): 2.1-2.9L. All medication, except insulin, are taken orally and includes Betamethasone depressant, Calcium, Movicol, Flexwell, Norspan patch, paracetamol (SR) tab 1300mg TDS, Panadol Osteo 665mg, esomeprazole tab (EC) 20mg daily, irbesartan tabs 300mg daily, escitalopram tab 20mg daily, diltiazem cap (CD) 240mg daily, metformin tab (ext. release) 1g mane, clopidogrel tab 25mg/75mg mane, and apixaban tabs 5mg/5mg BD (Jugenheimer et al., 2008).
Reflection
According to the clinical facilitator and based on nurse assessment, the patient needs pain management for faster postoperative care. She also needs close monitoring. The patient did not experience a reduction in pain, but it became consistent around the surgical wounds. It seems the patient developed complications during the surgical procedure. Antibiotics should help with any infections and Paracetamol and Panadol minimize pain on the affected sites.
Conclusion
Gallbladder diseases are often secondary to cholelithiasis. Some cases are asymptomatic, but others can progress to become symptomatic. Family history, ethnicity, gender, diet and nutrition, and medical history can increase the susceptibility or risk of developing gallbladder disease. Imaging techniques are used to diagnose gallbladder disease. The techniques have varying pros and cons, and rate of accuracy. The presenting symptoms and type of gallbladder disease determine the right imaging technique to use. Whereas surgical treatment is the most preferred for symptomatic patients, asymptomatic patients do not need treatment. Non-invasive treatment options are available for patients who are either unwilling or unable to undergo a surgical procedure. Creating awareness about the risk factors for gallbladder disease, especially cholelithiasis, and how to minimize the risk through exercise, and proper nutrition and diet, can help reduce cases of gallbladder disease and support provision of proper treatment.
References
Anderson, P. O., Knoben, J. E., & Troutman, W. G. (2010). Clinical drug data. New York: McGraw-Hill Medical.
Al-alem, F., Mattar, R. E., Madkhali, A., Alsharabi, A., Alsaif, F., & Hassanain, M. (April 26, 2017). Incidental Gallbladder Cancer.
Borzellino, G., & Cordiano, C. (2008). Biliary lithiasis: Basic science, current diagnosis, and management. Milan: Springer.
Bullock, ., Shane, ., & Hales, . (2012). Principles of Pathophysiology. Sydney: P. Ed Australia.
In Agresta, F., In Campanile, F. C., & In Vettoretto, N. (2014). Laparoscopic Cholecystectomy: An Evidence-based Guide.
In Cox, M. R., In Eslick, G. D., & In Padbury, R. (2018). The management of gallstone disease: A practical and evidence-based approach.
In Wang, D. Q.-H., & In Portincasa, P. A. M. (2017). Gallstones: Recent advances in epidemiology, pathogenesis, diagnosis and management.
Jugenheimer, M., Immenroth, M., Berg, T., & Brenner, J. (2008). Laparoscopic cholecystectomy. Heidelberg: Springer.
Krentz, A. (2012). Drug Therapy for Type 2 Diabetes. Springer Healthcare.
Lemone, P. (2013). Medical-Surgical Nursing (Australian Edition) Volumes 1-3. Melbourne: P. Ed Australia.
Nahikian-Nelms, M., & Sucher, K. (2015). Nutrition therapy and pathophysiology.
Talley, N. J. (2011). Clinical Gastroenterology: A Practical Problem-Based Approach.
Vizi, E. S., Fu?rst, S., & Zsilla, G. (2014). Receptors and Centrally Acting Drugs Pharmacokinetics and Drug Metabolism: Proceedings of the 4th Congress of the Hungarian Pharmacological Society, Budapest, 1985. Kent: Elsevier Science.